MIK665X
Total Payments
$99,829
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $71,995 | 1 | 0 |
| 2017 | $27,834 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $99,829 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE I OPEN LABEL MULTI CENTER STUDY TO CHARACTERIZE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF INTRAVENOUSLY ADMINISTERED MIK665 A MCL1 INHIBITOR IN PATIENTS WITH REFRACTORY OR RELAPSED LYMPHOMA OR MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $99,829 | 0 |
Top Doctors Receiving Payments for MIK665X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $99,829 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $99,829
- Total Doctors 0
- Transactions 2
About MIK665X
MIK665X is a drug associated with $99,829 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $71,995 was paid across 1 transactions to 0 doctors.
The most common payment nature for MIK665X is "Unspecified" ($99,829, 100.0% of total).
MIK665X is associated with 1 research study, including "PHASE I OPEN LABEL MULTI CENTER STUDY TO CHARACTERIZE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF INTRAVENOUSLY ADMINISTERED MIK665 A MCL1 INHIBITOR IN PATIENTS WITH REFRACTORY OR RELAPSED LYMPHOMA OR MULTIPLE MYELOMA" ($99,829).